Form 4: Oncocyte CFO Andrea James Increases Stake in Company Through Private Placement

Andrea James, CFO of Oncocyte Corp, reports purchasing 97,561 shares of common stock at $2.05 per share via a private placement, increasing her direct holdings to 151,231 shares.

Summary

• On February 7, 2025, Andrea James, the Chief Financial Officer of Oncocyte Corp, acquired 97,561 shares of Oncocyte's common stock.
• The shares were purchased at a price of $2.05 per share.
• This transaction was part of a private placement agreement between Oncocyte and signatory investors.
• Following the transaction, Andrea James directly owns 151,231 shares of Oncocyte's common stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the CFO's purchase suggests confidence in the company, but it's a routine filing and doesn't contain groundbreaking news.

Positives

• The CFO's increased investment in the company may signal confidence in Oncocyte's future prospects.

Industry Context

Insider transactions are closely monitored as they can provide insights into a company's prospects. A purchase by a key executive like the CFO is often seen as a positive signal.

Comparison to Industry Standards

• Comparing this transaction to other insider purchases in the biotech industry, it's important to consider the size of the purchase relative to the executive's existing holdings and the company's market capitalization.
• For example, if the CEO of a similarly sized company like Exact Sciences (EXAS) or Guardant Health (GH) made a comparable purchase, it would be viewed in a similar light.
• However, the impact can vary based on the company's performance and overall market sentiment.

Stakeholder Impact

• Shareholders may view the CFO's purchase as a positive sign, potentially increasing investor confidence.
• Employees may also see this as a sign of stability and confidence in the company's future.

Key Dates

Keywords

Oncocyte, Andrea James, CFO, private placement, common stock, Form 4, insider trading, OCX